Catalyst Pharma sees net price of drug, once free, topping $300 000

  • Catalyst Pharma indicated that the net price of its Lambert-Eaton myasthenic syndrome treatment Firdapse will have a net cost of more than $300 000, as reported NASDAQ Monday.

  • The news comes after Senator Bernie Sanders asked the company to justify the drug's list cost of $375 000 a year.

  • Meanwhile, Catalyst indicated that rebates and various discounts will reduce the final cost of the therapy by 15 percent to 20 percent.

  • Catalyst acquired rights to Firdapse, which had previously been available for free, from BioMarin Pharmaceutical in 2012.

  • An Express Scripts spokeswoman argued that the price "takes advantage of vulnerable patients who need this medication," adding that Catalyst is an example of a company misusing the Orphan Drug Act.

  • Meanwhile, Catalyst CEO Patrick McEnany said the company will respond to Sanders in a timely manner.

  • FirstWord Reports: Providing insight, analysis and expert opinion on important Pharma trends and challenging issues <Click here>